基于SLCO1B1基因的临床决策支持降低辛伐他汀相关肌肉症状风险

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-05-01 Epub Date: 2023-05-26 DOI:10.2217/pgs-2023-0056

Amanda Massmann, Joel Van Heukelom, Robert C Green, Catherine Hajek, Madison R Hickingbotham, Eric A Larson, Christine Y Lu, Ann Chen Wu, Emilie S Zoltick, Kurt D Christensen, April Schultz

{"title":"基于SLCO1B1基因的临床决策支持降低辛伐他汀相关肌肉症状风险","authors":"Amanda Massmann, Joel Van Heukelom, Robert C Green, Catherine Hajek, Madison R Hickingbotham, Eric A Larson, Christine Y Lu, Ann Chen Wu, Emilie S Zoltick, Kurt D Christensen, April Schultz","doi":"10.2217/pgs-2023-0056","DOIUrl":null,"url":null,"abstract":"Background: SLCO1B1 variants are known to be a strong predictor of statin-associated muscle symptoms (SAMS) risk with simvastatin. Methods: The authors conducted a retrospective chart review on 20,341 patients who had SLCO1B1 genotyping to quantify the uptake of clinical decision support (CDS) for genetic variants known to impact SAMS risk. Results: A total of 182 patients had 417 CDS alerts generated, and 150 of these patients (82.4%) received pharmacotherapy that did not increase risks for SAMS. Providers were more likely to cancel simvastatin orders in response to CDS alerts if genotyping had been done prior to the first simvastatin prescription than after (94.1% vs 28.5%, respectively; p < 0.001). Conclusion: CDS significantly reduces simvastatin prescribing at doses associated with SAMS.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242433/pdf/","citationCount":"0","resultStr":"{\"title\":\"SLCO1B1 gene-based clinical decision support reduces statin-associated muscle symptoms risk with simvastatin.\",\"authors\":\"Amanda Massmann, Joel Van Heukelom, Robert C Green, Catherine Hajek, Madison R Hickingbotham, Eric A Larson, Christine Y Lu, Ann Chen Wu, Emilie S Zoltick, Kurt D Christensen, April Schultz\",\"doi\":\"10.2217/pgs-2023-0056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: SLCO1B1 variants are known to be a strong predictor of statin-associated muscle symptoms (SAMS) risk with simvastatin. Methods: The authors conducted a retrospective chart review on 20,341 patients who had SLCO1B1 genotyping to quantify the uptake of clinical decision support (CDS) for genetic variants known to impact SAMS risk. Results: A total of 182 patients had 417 CDS alerts generated, and 150 of these patients (82.4%) received pharmacotherapy that did not increase risks for SAMS. Providers were more likely to cancel simvastatin orders in response to CDS alerts if genotyping had been done prior to the first simvastatin prescription than after (94.1% vs 28.5%, respectively; p < 0.001). Conclusion: CDS significantly reduces simvastatin prescribing at doses associated with SAMS.\",\"PeriodicalId\":20018,\"journal\":{\"name\":\"Pharmacogenomics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242433/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pgs-2023-0056\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/5/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0056","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

背景:已知SLCO1B1变异是辛伐他汀患者他汀相关肌肉症状(SAMS)风险的一个强有力的预测因子。方法:作者对20,341例SLCO1B1基因分型患者进行了回顾性图表回顾，以量化临床决策支持(CDS)对已知影响SAMS风险的遗传变异的吸收。结果:182例患者共产生417例CDS警报，其中150例(82.4%)接受了不增加SAMS风险的药物治疗。如果在第一次辛伐他汀处方前进行基因分型，而不是在第一次辛伐他汀处方后进行基因分型，提供者更有可能因CDS警报而取消辛伐他汀订单(分别为94.1%和28.5%);结论:CDS显著减少了与SAMS相关剂量的辛伐他汀处方。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

SLCO1B1 gene-based clinical decision support reduces statin-associated muscle symptoms risk with simvastatin.

Background: SLCO1B1 variants are known to be a strong predictor of statin-associated muscle symptoms (SAMS) risk with simvastatin. Methods: The authors conducted a retrospective chart review on 20,341 patients who had SLCO1B1 genotyping to quantify the uptake of clinical decision support (CDS) for genetic variants known to impact SAMS risk. Results: A total of 182 patients had 417 CDS alerts generated, and 150 of these patients (82.4%) received pharmacotherapy that did not increase risks for SAMS. Providers were more likely to cancel simvastatin orders in response to CDS alerts if genotyping had been done prior to the first simvastatin prescription than after (94.1% vs 28.5%, respectively; p < 0.001). Conclusion: CDS significantly reduces simvastatin prescribing at doses associated with SAMS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.